New Anti-Eosinophil Drugs for Asthma and COPD
Top Cited Papers
- 1 December 2017
- Vol. 152 (6) , 1276-1282
- https://doi.org/10.1016/j.chest.2017.05.019
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Eosinophils: changing perspectives in health and diseaseNature Reviews Immunology, 2012
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEuropean Respiratory Journal, 2012
- Global asthma prevalence in adults: findings from the cross-sectional world health surveyBMC Public Health, 2012
- Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthmaExpert Opinion on Biological Therapy, 2011
- Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, at-Risk Phenotype among Patients with AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2010
- What targeting eosinophils has taught us about their role in diseasesJournal of Allergy and Clinical Immunology, 2010
- Effect of omalizumab on peripheral blood eosinophilia in allergic asthmaRespiratory Medicine, 2010
- Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trialEuropean Respiratory Journal, 2007
- Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatmentEuropean Respiratory Journal, 2006
- Inflammatory cell mapping of the respiratory tract in fatal asthmaClinical and Experimental Allergy, 2005